Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Brivaracetam in Epilepsy
NCT01728077Phase 3Completed
- Sponsor
- UCB
- Start
- Oct 2012
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of brivaracetam in epilepsy, sponsored by UCB. Primary endpoints: Incidence of Treatment Emergent Adverse Events up to 46 months, Percentage of Subjects Withdrawn Due to an Adverse Event up to 46 months and 1 more. Started Oct 2012; status: completed.
02
Drugs
brivaracetam
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT01728077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01728077.